The difference in TET between patients treated with stem cells compared to placebo was 61.0 s (three months) (95% confidence interval (CI): -2.9 to 124.8; p 1⁄4 0.06), 46.2 s  (six months) (95% CI: -28.0 to 120.4; p 1⁄4 0.22), and 36.6 s  (12 months) (95% CI: -56.1 to 129.2; p 1⁄4 0.43); angina frequency was improved at six months (relative risk: 0.63, p 1⁄4 0.05). Major adverse cv incidents were 67.9% (in patients with the standard of care), 42.9% (in active control), and 46.0% [in patients receiving CD34+]. Here, CD34 is linked to angina pectoris.